PACIFIC-5: a phase III clinical trial of consolidation durvalumab in patients with unresectable stage III NSCLC and no progression after concurrent or sequential chemoradiotherapy
Authors
Mustafa Dikilitaş (ORCID: https://orcid.org/0000-0002-3763-7529)
Rui Mao (ORCID: https://orcid.org/0000-0002-6737-2939)
Lühua Wang (ORCID: https://orcid.org/0000-0002-5272-1681)
Hong Ge (ORCID: https://orcid.org/0000-0002-2958-3866)
PACIFIC-5: a phase III clinical trial of consolidation durvalumab in patients with unresectable stage III NSCLC and no progression after concurrent or sequential chemoradiotherapy
Mustafa Dikilitaş, Rui Mao, Lühua Wang, Hong Ge et al.
Citations
1 citations
Journal
Journal of Hematology & Oncology
Topics
Lung Cancer Treatments and Mutations
Field-Weighted Citation Impact (FWCI)
1.52
article
PACIFIC-5: a phase III clinical trial of consolidation durvalumab in patients with unresectable stage III NSCLC and no progression after concurrent or sequential chemoradiotherapy
Mustafa Dikilitaş, Rui Mao, Lühua Wang, Hong Ge, Timuçin Çil, E Mingyan, Dongqing Lv, Yi Pan, Maciej Jerzy Krzakowski, Lin Wu, Nan Bi, Wei Zhang, Yi-Long Lung Cancer Wu, Jianguo Sun, B. Zhang, Young‐Chul Kim, Chih‐Liang Wang, Yanjiao Yang, Mehmet Ali Nahit Sendur, Zhengfei Zhu
article en
1 citations
Abstract
No abstract available for this paper.
Publication Tag
Journal of Hematology & OncologyVol. 18(1)
Institutions
Tongji University (CN), Central South University (CN), Ankara University (TR), Army Medical University (CN), Harbin Medical University (CN), Dalian Medical University (CN), Chinese Academy of Medical Sciences & Peking Union Medical College (CN), Inonu University (TR), Wenzhou Medical University (CN), Chang Gung Memorial Hospital (TW), Zhengzhou University (CN), National Cancer Center (US), Fudan University Shanghai Cancer Center (CN), Second Affiliated Hospital of Chongqing Medical University (CN), Memorial Ankara Hospital (TR), Third Affiliated Hospital of Harbin Medical University (CN), Hunan Cancer Hospital (CN), Shanghai Pulmonary Hospital (CN), Başkent University Hospital (TR), AstraZeneca (Poland) (PL), Henan Cancer Hospital (CN), Guangdong Academy of Medical Sciences (CN), Chonnam National University Hwasun Hospital (KR), The Maria Sklodowska-Curie National Research Institute of Oncology (PL), Zhejiang Taizhou Hospital (CN), AstraZeneca (Germany) (DE), Turgut Özal University (TR), Chongqing Medical University (CN)